Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OCUL

OCUL - Ocular Therapeutix Inc Stock Price, Fair Value and News

$10.27-0.58 (-5.35%)
Market Closed

11/100

OCUL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

OCUL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.22

Target 3M

$9.24

Target 6M

$8.73

OCUL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCUL Price Action

Last 7 days

-10.1%

Last 30 days

-16.5%

Last 90 days

-13.1%

Trailing 12 Months

30%

OCUL RSI Chart

OCUL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCUL Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-8.76

Price/Sales (Trailing)

39.22

Price/Free Cashflow

-10.97

OCUL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.22

Target 3M

$9.24

Target 6M

$8.73

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

55.8M

Rev. Growth (Yr)

-5.71%

Rev. Growth (Qtr)

8.06%

OCUL Earnings

Earnings (TTM)

-249.7M

Earnings Growth (Yr)

-90.22%

Earnings Growth (Qtr)

-2.37%

OCUL Profitability

Return on Equity

-96.69%

Return on Assets

-60.77%

Free Cashflow Yield

-9.12%

OCUL Investor Care

Shares Dilution (1Y)

35.51%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202559.6M56.7M55.8M0
202459.8M61.1M61.4M63.7M
202351.7M54.6M57.7M58.4M
202249.4M49.9M49.7M51.5M
202122.1M32.3M38.6M43.5M
20206.3M7.3M12.3M17.4M
20192.1M2.1M2.5M4.2M
20181.8M2.0M2.0M2.0M
20171.9M1.9M1.9M1.9M
20161.8M1.8M1.8M1.9M
20151.2M1.5M1.8M1.8M
2014200.5K391.0K581.5K772.0K
201200010.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Ocular Therapeutix Inc

OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
 CEO
 WEBSITEocutx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES274

Ocular Therapeutix Inc Frequently Asked Questions

OCUL is the stock ticker symbol of Ocular Therapeutix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ocular Therapeutix Inc is 2.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OCUL's fair value in chart for subscribers.

The fair value guage provides a quick view whether OCUL is over valued or under valued. Whether Ocular Therapeutix Inc is cheap or expensive depends on the assumptions which impact Ocular Therapeutix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUL.

As of Wed Jan 28 2026, OCUL's PE ratio (Price to Earnings) is -8.76 and Price to Sales (PS) ratio is 39.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ocular Therapeutix Inc has provided 0.053 (multiply by 100 for percentage) rate of return.